- Home
- RDHL vs TOVX Comparison
RDHL vs TOVX Comparison
Compare RDHL & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- TOVX
- Stock Information
- Founded
- RDHL 2009
- TOVX 2001
- Country
- RDHL Israel
- TOVX United States
- Employees
- RDHL N/A
- TOVX N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- TOVX Health Care
- Exchange
- RDHL Nasdaq
- TOVX Nasdaq
- Market Cap
- RDHL 4.3M
- TOVX 3.8M
- IPO Year
- RDHL N/A
- TOVX 2006
- Fundamental
- Price
- RDHL $2.18
- TOVX $0.50
- Analyst Decision
- RDHL
- TOVX Hold
- Analyst Count
- RDHL 0
- TOVX 1
- Target Price
- RDHL N/A
- TOVX N/A
- AVG Volume (30 Days)
- RDHL 17.8K
- TOVX 172.8K
- Earning Date
- RDHL 08-28-2025
- TOVX 08-12-2025
- Dividend Yield
- RDHL N/A
- TOVX N/A
- EPS Growth
- RDHL N/A
- TOVX N/A
- EPS
- RDHL N/A
- TOVX N/A
- Revenue
- RDHL $8,042,999.00
- TOVX N/A
- Revenue This Year
- RDHL $381.91
- TOVX N/A
- Revenue Next Year
- RDHL N/A
- TOVX N/A
- P/E Ratio
- RDHL N/A
- TOVX N/A
- Revenue Growth
- RDHL 23.17
- TOVX N/A
- 52 Week Low
- RDHL $1.71
- TOVX $0.40
- 52 Week High
- RDHL $20.28
- TOVX $7.37
- Technical
- Relative Strength Index (RSI)
- RDHL 65.22
- TOVX 51.01
- Support Level
- RDHL $2.00
- TOVX $0.42
- Resistance Level
- RDHL $2.08
- TOVX $0.48
- Average True Range (ATR)
- RDHL 0.09
- TOVX 0.03
- MACD
- RDHL 0.03
- TOVX 0.02
- Stochastic Oscillator
- RDHL 97.73
- TOVX 82.80
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.